Sign in →

Test Code HIBS Haemophilus influenzae Type B Antibody, IgG, Serum

Performing Laboratory

Mayo Medical Laboratories in Rochester

Reporting Name

Haemophilus influenzae B Ab, IgG, S

Specimen Type

Serum


Specimen Required


Container/Tube: 

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL


Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

NA

Other

NA

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 7 days
  Frozen  7 days

Specimen Minimum Volume

0.2 mL

Day(s) and Time(s) Performed

Tuesday, Thursday; 9 a.m.

Specimen Retention Time

2 weeks

Analytic Time

Same day/1 day

Reference Values

≥0.15 mg/L

Useful For

Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine

 

Assessing immunity against HIB

 

Aiding in the evaluation of immunodeficiency

Method Name

Enzyme Immunoassay (EIA)

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86684

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HIBS Haemophilus influenzae B Ab, IgG, S 11257-3

 

Result ID Test Result Name Result LOINC Value
83261 Haemophilus influenzae B Ab, IgG, S 11257-3

Clinical Information

Haemophilus influenzae type B (HIB) is an encapsulated gram-negative cocco-bacillary bacterium that can cause devastating disease in young children including meningitis, bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis.

 

One of the great advances in modern medicine has been the development of an effective vaccine against HIB. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this EIA technique.

Interpretation

An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mg/L postimmunization.(1) Furthermore, studies have shown that the response to HIB vaccine is age-related.

 

By testing pre- and postvaccination patient serum specimens, this test may be used to aid diagnosis of immunodeficiency.

Cautions

This assay does not provide diagnostic proof of the presence or absence of immune deficiency. Results must be confirmed by clinical findings and other laboratory tests.

Clinical Reference

1. Peltola H, Kayhty H, Virtanen M, et al: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310(24):1561-1566

2. Berger M: Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. J Pediatr 1987;110(2):325-328

Method Description

Microwells are precoated with the Haemophilus influenzae type B (HIB) capsular polysaccharide antigen conjugated to human serum albumin. The calibrators, controls, and diluted patient specimens are added to the wells and antibodies recognizing the HIB antigen bind during the first incubation. After washing the wells to remove all unbound proteins, purified peroxidase-labeled rabbit antihuman IgG (gamma chain specific) conjugate is added. The conjugate binds to the captured human antibody and the excess unbound conjugate is removed by a further wash step. The bound conjugate is visualized with 3,3', 5,5' tetramethylbenzidine (TMB) substrate, which gives a blue reaction product, the intensity of which is proportional to the concentration of antibody in the specimen. Phosphoric acid is added to each well to stop the reaction. This produces a yellow end point color, which is read at 450 nm.(Madore DV, Anderson P, Baxter BD, et al: Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type B polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996;3[1]:84-88)